Suppliers and packagers for ROGAINE EXTRA STRENGTH (FOR MEN)

ROGAINE EXTRA STRENGTH (FOR MEN)

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Kenvue Brands	ROGAINE EXTRA STRENGTH (FOR MEN)	minoxidil	SOLUTION;TOPICAL	020834	NDA	Kenvue Brands LLC	69968-0089-1	1 BOTTLE, PLASTIC in 1 CARTON (69968-0089-1) / 60 mL in 1 BOTTLE, PLASTIC	2010-07-16
Kenvue Brands	ROGAINE EXTRA STRENGTH (FOR MEN)	minoxidil	SOLUTION;TOPICAL	020834	NDA	Kenvue Brands LLC	69968-0089-3	3 BOTTLE, PLASTIC in 1 CARTON (69968-0089-3) / 60 mL in 1 BOTTLE, PLASTIC	2010-07-16

ROGAINE EXTRA STRENGTH (FOR MEN) SUPPLIER LANDSCAPE

Last updated: February 19, 2026

This analysis identifies key suppliers for the active pharmaceutical ingredient (API) and critical excipients used in the formulation of ROGAINE EXTRA STRENGTH (FOR MEN). It examines supplier characteristics, potential risks, and market positioning to inform R&D and investment strategies.

WHO ARE THE PRIMARY API SUPPLIERS?

The active pharmaceutical ingredient in ROGAINE EXTRA STRENGTH (FOR MEN) is minoxidil. Sourcing minoxidil involves identifying manufacturers with current Good Manufacturing Practices (cGMP) compliance and robust quality control systems.

MINOXIDIL MANUFACTURERS

Minoxidil is a vasodilatory drug initially developed for hypertension. Its repurposing for androgenetic alopecia led to significant market demand, supported by several global API manufacturers. The primary suppliers typically operate large-scale chemical synthesis facilities.

• Major Manufacturers:
  • Anacor Pharmaceuticals, Inc. (now Pfizer Inc.): While Anacor was acquired by Pfizer, its historical involvement in topical minoxidil formulations positions its former manufacturing capabilities as relevant. Pfizer's global supply chain infrastructure is extensive.
  • Core Scientifics Inc.: A U.S.-based supplier specializing in APIs, including minoxidil. They emphasize cGMP compliance and regulatory support.
  • Alps Pharmaceutical Industry Co., Ltd.: A Japanese manufacturer with a portfolio of APIs, including minoxidil. They operate under stringent Japanese pharmaceutical regulations.
  • Sami Labs Limited: An Indian pharmaceutical company that manufactures various APIs, including minoxidil, catering to global markets.

The choice of minoxidil supplier is critical, impacting product purity, consistency, and regulatory adherence. Manufacturers must demonstrate a track record of reliable production and a deep understanding of global pharmacopeial standards (e.g., USP, EP, JP).

WHAT ARE THE KEY EXCIPIENTS AND THEIR SUPPLIERS?

Beyond the API, ROGAINE EXTRA STRENGTH (FOR MEN) relies on several excipients to ensure stability, delivery, and efficacy. The primary formulation is a topical solution.

CRITICAL EXCIPIENTS AND POTENTIAL SUPPLIERS

The formulation of topical minoxidil solutions typically includes solvents, penetration enhancers, and stabilizers.

• Propylene Glycol: This is a common solvent and humectant in topical formulations, aiding in drug solubility and skin penetration.
  • Suppliers: Dow Chemical Company, LyondellBasell Industries, INEOS. These companies are large-scale producers of propylene oxide, the precursor to propylene glycol, ensuring consistent supply.
• Ethanol (Alcohol): Acts as a solvent and contributes to the rapid drying of the topical application.
  • Suppliers: Archer Daniels Midland Company (ADM), POET LLC, Green Plains Inc. These companies are major ethanol producers, primarily for fuel, but also supply industrial and pharmaceutical grades. Pharmaceutical-grade ethanol requires specific purification processes and regulatory compliance.
• Water: Purified water is a fundamental component. Pharmaceutical water is typically produced through distillation, deionization, or reverse osmosis, meeting strict pharmacopeial standards.
  • Suppliers: While not typically purchased as a bulk commodity from a single named supplier, pharmaceutical manufacturers maintain sophisticated on-site water purification systems or contract with specialized water treatment companies. Key components for these systems are sourced from companies like Suez Water Technologies & Solutions or Veolia Water Technologies.
• Citric Acid: Used as a pH adjuster to maintain the optimal acidic environment for minoxidil stability and skin compatibility.
  • Suppliers: Cargill, Incorporated, Tate & Lyle PLC, DSM. These companies are major producers of citric acid through fermentation processes.
• Other Stabilizers/Preservatives (e.g., Butylated Hydroxytoluene - BHT): Antioxidants like BHT may be included to prevent degradation of other components.
  • Suppliers: Eastman Chemical Company, Lanxess AG. These companies are known for producing specialty chemicals, including antioxidants used in pharmaceutical and food applications.

The selection of excipient suppliers is governed by their ability to provide materials meeting pharmacopeial grade specifications, consistent quality, and a stable supply chain. Documentation regarding sourcing, manufacturing, and quality control is paramount.

WHAT ARE THE SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The pharmaceutical supply chain for a product like ROGAINE EXTRA STRENGTH (FOR MEN) is subject to various risks, including regulatory changes, geopolitical instability, and raw material shortages.

IDENTIFIED RISKS

• API Sourcing Dependence: Reliance on a limited number of minoxidil manufacturers can create vulnerability. A disruption at one major supplier could significantly impact product availability.
• Excipient Quality Variations: Inconsistent quality of excipients, particularly from less regulated sources, can lead to batch failures, reduced efficacy, or adverse patient reactions.
• Regulatory Scrutiny: Pharmaceutical ingredients are subject to strict regulatory oversight by agencies like the FDA, EMA, and others. Changes in regulations or failure to comply can lead to product recalls or import restrictions.
• Geopolitical and Environmental Factors: Global events, natural disasters, or trade disputes can disrupt the availability and cost of raw materials and finished APIs.
• Intellectual Property and Manufacturing Rights: Ensuring that API and excipient suppliers operate with appropriate intellectual property rights and manufacturing licenses is essential.

MITIGATION STRATEGIES

• Supplier Diversification: Establishing relationships with multiple qualified suppliers for both the API and critical excipients reduces dependence on any single entity.
• Robust Quality Agreements: Implementing stringent quality agreements with suppliers that clearly define specifications, testing protocols, change control procedures, and audit rights.
• Auditing and Qualification: Conducting regular on-site audits of supplier facilities to verify cGMP compliance, manufacturing processes, and quality management systems.
• Supply Chain Mapping and Transparency: Gaining visibility into the upstream supply chain of key raw materials used by API and excipient manufacturers.
• Inventory Management and Safety Stock: Maintaining adequate safety stock levels for critical raw materials and finished APIs to buffer against short-term supply disruptions.
• Regulatory Intelligence: Proactively monitoring changes in pharmaceutical regulations in key markets and ensuring suppliers are compliant.

HOW HAS THE SUPPLY CHAIN EVOLVED?

The supply chain for minoxidil and its associated excipients has matured, driven by increased global demand and evolving regulatory landscapes.

HISTORICAL AND CURRENT TRENDS

• Shift to Asia: In recent decades, a significant portion of API manufacturing, including minoxidil, has shifted to India and China due to cost advantages and the development of robust chemical synthesis capabilities. This has led to increased competition but also concentrated risk in specific geographic regions.
• Increased cGMP Enforcement: Regulatory bodies worldwide have intensified scrutiny of API and excipient manufacturing. This has driven higher quality standards but also increased compliance costs for suppliers. Manufacturers demonstrating strong cGMP adherence are increasingly favored.
• Focus on Sustainability: Growing pressure for environmentally sustainable manufacturing practices is influencing supplier selection. Companies that can demonstrate green chemistry initiatives and responsible waste management may gain a competitive advantage.
• Technological Advancements: Innovations in chemical synthesis and purification technologies allow for more efficient and higher-purity production of minoxidil and excipients. Suppliers investing in these technologies can offer superior products.
• Consolidation: Mergers and acquisitions within the pharmaceutical and chemical industries have led to consolidation among API and excipient manufacturers. This can impact pricing and supplier availability.

WHAT IS THE MARKET POSITIONING OF KEY SUPPLIERS?

Suppliers are differentiated by their manufacturing capacity, regulatory compliance, geographic reach, and specialization.

SUPPLIER DIFFERENTIATION

• Large-Scale, Integrated Manufacturers: Companies like Pfizer (through acquisition) and major chemical conglomerates have the capacity to produce high volumes of materials. Their strengths lie in economies of scale and established global distribution networks.
• Specialty API Manufacturers: Companies like Core Scientifics Inc. often focus on a narrower range of APIs, offering specialized expertise and regulatory support. They may cater to niche markets or companies requiring tailored manufacturing solutions.
• Regional Dominance: Manufacturers based in India and China often compete on cost, while European and North American suppliers may emphasize higher perceived quality, robust regulatory support, and shorter lead times for specific markets.
• Excipient Specialists: Companies like Dow Chemical and ADM are global leaders in their respective excipient categories, providing high-quality, bulk materials with established supply chains.

The positioning of these suppliers directly impacts the cost, quality, and reliability of the raw materials used in ROGAINE EXTRA STRENGTH (FOR MEN). Manufacturers must evaluate suppliers based on a balance of these factors.

Key Takeaways

1. API Sourcing Focus: Minoxidil is the primary API, with established global manufacturers in North America, Europe, and Asia. Key suppliers include Pfizer (via Anacor acquisition), Core Scientifics Inc., Alps Pharmaceutical Industry Co., Ltd., and Sami Labs Limited.
2. Excipient Dependency: Critical excipients such as propylene glycol, ethanol, purified water, citric acid, and potentially BHT are essential. Major suppliers for these include Dow Chemical, LyondellBasell, ADM, POET, Cargill, Tate & Lyle, Eastman Chemical, and Lanxess AG.
3. Risk Mitigation is Paramount: Supply chain risks include API sourcing dependence, excipient quality variations, regulatory scrutiny, and geopolitical factors. Mitigation strategies involve supplier diversification, rigorous quality agreements, regular audits, and supply chain transparency.
4. Evolving Supply Chain Dynamics: The market has seen a shift towards Asian manufacturing for APIs, increased regulatory enforcement, and growing emphasis on sustainability and technological advancements.
5. Supplier Differentiation: Suppliers are distinguished by manufacturing scale, regulatory standing, geographic presence, and specialization, influencing product cost, quality, and reliability.

FAQs

1. What are the primary regulatory requirements for minoxidil API suppliers? Minoxidil API suppliers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others relevant to the target markets. This includes robust quality management systems, stringent process controls, thorough documentation, and successful inspections by regulatory authorities.

2. How is the pharmaceutical grade of ethanol distinguished from industrial grade? Pharmaceutical-grade ethanol is produced to meet pharmacopeial standards (e.g., USP, EP) and undergoes rigorous purification processes to remove impurities. It is manufactured under cGMP conditions and is free from denaturants that may be added to industrial grades. Certificates of Analysis (CoAs) from suppliers must confirm compliance with specific pharmacopeial monographs.

3. What are the implications of relying on suppliers primarily located in Asia for minoxidil? Reliance on Asian suppliers can offer cost advantages but also introduces risks related to geopolitical instability, longer lead times, potential for counterfeit materials, and variations in regulatory enforcement compared to Western markets. Companies must implement thorough due diligence, frequent auditing, and robust quality control measures when sourcing from this region.

4. How frequently should a pharmaceutical company audit its critical API and excipient suppliers? The frequency of supplier audits depends on a risk-based approach. Critical suppliers of the API and high-impact excipients typically warrant annual audits. For less critical materials or suppliers with a proven track record of consistent performance, audits may occur biennially. Unannounced audits may also be conducted to assess routine operating conditions.

5. What measures can be taken to ensure the consistent quality of propylene glycol used in topical formulations? To ensure consistent quality of propylene glycol, companies should establish detailed specifications that align with relevant pharmacopeias (e.g., USP/NF). They must also enter into quality agreements with suppliers that mandate strict adherence to cGMP, provide Certificates of Analysis for each batch, and allow for periodic audits of the supplier's manufacturing facilities and quality control laboratories.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/pharmaceutical-product-regulation/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/ [4] European Pharmacopoeia. (n.d.). EDQM. Retrieved from https://www.edqm.eu/